Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status.

Pharmacogenetics and genomics - 1 Dec 2005

Ieiri Ichiro, Kimura Miyuki, Irie Shin, Urae Akinori, Otsubo Kenji, Ishizaki Takashi

Abstract excerpt

OBJECTIVES: The aim of this study was to investigate the impact of CYP2C19 polymorphism on the extent of the interaction and on the pharmacokinetics and pharmacodynamics of ticlopidine. METHODS: Homozygous (hmEMs) and heterozygous extensive metabolizers (htEMs), and poor metabolizers (PMs, n = 6 each) took an oral dose (20 mg) of omeprazole. After a 1-week washout period, each subject received ticlopidine (200...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Enzyme Inhibitors

Share to Genotype

Share to Mixed Function Oxygenases

Share to Omeprazole

Share to Ticlopidine

Source

Identifiers

PMID: 16272957
DOI: 10.1097/01213011-200512000-00003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status.PMID 16272957Read ↗

Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.Semantic proximity Read ↗

The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.Semantic proximity Read ↗

Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.Semantic proximity Read ↗

Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem.Semantic proximity Read ↗

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.Semantic proximity Read ↗

Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.Semantic proximity Read ↗

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.Semantic proximity Read ↗

The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity.Semantic proximity Read ↗

Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.Semantic proximity Read ↗

Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.Semantic proximity Read ↗

The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.